ChemoCentryx (CCXI) Announces CCX168 Phase II CLEAR Met Primary Endpoint
Tweet Send to a Friend
ChemoCentryx, Inc., (Nasdaq: CCXI) announced positive top-line data from its’ Phase II CLEAR trial with CCX168 in patients with anti-neutrophil ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
